▶ 調査レポート

静脈注射用免疫グロブリン(IVIG)の世界市場2022-2031:産業分析、規模、シェア、成長、動向、予測

• 英文タイトル:Intravenous Immunoglobulin Market (Indication: Chronic Inflammatory Demyelinating Polyneuropathy, Primary Humoral Immunodeficiency, Idiopathic Thrombocytopenic Purpura, Guillain-Barre Syndrome, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, Hypogammaglobulinemia, Chronic Lymphocytic Leukemia, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Transparency Market Researchが調査・発行した産業分析レポートです。静脈注射用免疫グロブリン(IVIG)の世界市場2022-2031:産業分析、規模、シェア、成長、動向、予測 / Intravenous Immunoglobulin Market (Indication: Chronic Inflammatory Demyelinating Polyneuropathy, Primary Humoral Immunodeficiency, Idiopathic Thrombocytopenic Purpura, Guillain-Barre Syndrome, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, Hypogammaglobulinemia, Chronic Lymphocytic Leukemia, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031 / MRC2207A099資料のイメージです。• レポートコード:MRC2207A099
• 出版社/出版日:Transparency Market Research / 2022年5月
• レポート形態:英文、PDF、232ページ
• 納品方法:Eメール
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥857,660 (USD5,795)▷ お問い合わせ
  Multi User¥1,301,660 (USD8,795)▷ お問い合わせ
  Corporate License¥1,745,660 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
トランスペアレンシー・マーケット・リサーチ社の本調査レポートでは、世界の静脈注射用免疫グロブリン(IVIG)市場について総合的に調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、市場動向、疾患別(慢性炎症性脱髄性多発神経炎、原発性体液性免疫不全、特発性血小板減少性紫斑病、ギランバレー症候群、その他)分析、エンドユーザー別分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、企業情報などの内容をまとめております。なお、本書に掲載されている企業情報にはBaxalta Incorporated、Biotest AG、China Biologic Products, Inc.、CSL Behring LLC、Grifols S.A.、Kedrion S.p.A.、LFB Biomedicaments S.A.、Octapharma AG、Sanquin Plasma Products B.V.などが含まれています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・市場動向
・世界の静脈注射用免疫グロブリン(IVIG)市場規模:疾患別(慢性炎症性脱髄性多発神経炎、原発性体液性免疫不全、特発性血小板減少性紫斑病、ギランバレー症候群、その他)
・世界の静脈注射用免疫グロブリン(IVIG)市場規模:エンドユーザー別
・世界の静脈注射用免疫グロブリン(IVIG)市場規模:地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)
・企業情報

Intravenous Immunoglobulin Market – Scope of Report

TMR’s report on the global intravenous immunoglobulin market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global intravenous immunoglobulin market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global intravenous immunoglobulin market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the intravenous immunoglobulin market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global intravenous immunoglobulin market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global intravenous immunoglobulin market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global intravenous immunoglobulin market.

The report delves into the competitive landscape of the global intravenous immunoglobulin market. Key players operating in the global intravenous immunoglobulin market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global intravenous immunoglobulin market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market intravenous immunoglobulin.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

レポート目次

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
3. Executive Summary
3.1. Global Intravenous Immunoglobulin (IVIG): Market Snapshot
3.2. Market Share Analysis, by Region, 2017
3.3. Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Map
4. Market Overview
4.1. Indication Overview
4.2. Global Intravenous Immunoglobulin (IVIG) Market: Key Industry Developments
4.3. Global Intravenous Immunoglobulin (IVIG) Market: Market Indicators
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.2.1. Rise in prevalence of autoimmune disorders
5.2.2. Increase in global geriatric population
5.2.3. Growing usage in off-label indications
5.2.4. Improved technology for production and purification methods
5.2.5. Favorable government initiatives and approvals
5.2.6. Increase in health care spending & improving health care infrastructure
5.2.7. Rise in incidence of hematological, neurological disorders
5.3. Restraints
5.3.1. High cost of treatment
5.3.2. Chronic side effects
5.3.3. Supply demand gaps
5.3.4. Alternate therapies such as subcutaneous infusion IG (SCIG) and recombinant Indications
5.4. Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Analysis
5.5. Opportunities
5.5.1. Application in newer indications
5.5.2. Increasing global plasma yield to offer significant opportunities to new entrants
5.6. Key Trends
5.7. Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2017–2031
5.8. Value Chain Analysis
5.9. Global Intravenous Immunoglobulin (IVIG) Market Outlook
6. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication
6.1. Key Findings
6.2. Introduction
6.3. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication
6.4. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication
6.4.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
6.4.2. Primary Humoral Immunodeficiency
6.4.3. Idiopathic Thrombocytopenic Purpura (ITP)
6.4.4. Guillain-Barre Syndrome
6.4.5. Myasthenia Gravis
6.4.6. Multifocal Motor Neuropathy (MMN)
6.4.7. Kawasaki Disease
6.4.8. Hypogammaglobulinemia
6.4.9. Chronic Lymphocytic Leukemia
6.4.10. Others
6.5. Market Attractiveness Analysis, by Indication
6.6. Key Trends
7. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
7.1. Key Findings
7.2. Introduction
7.3. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user
7.4. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
7.4.1. Hospitals
7.4.2. Clinics
7.4.3. Home Care
7.5. Market Attractiveness Analysis, by End-user
7.6. Key Trends
8. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Region
8.1. Global Intravenous Immunoglobulin (IVIG) Market Snapshot, by Country
8.2. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region
8.3. Intravenous Immunoglobulin (IVIG) Market Forecast, by Region
8.4. Market Attractiveness Analysis, by Region
9. North America Intravenous Immunoglobulin (IVIG) Market Analysis
9.1. Key Findings
9.2. Market Overview
9.3. Market Analysis, by Indication
9.3.1. Market Value Share Analysis, by Indication
9.3.2. Market Size (US$ Mn) Forecast, by Indication
9.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9.3.2.2. Primary Humoral Immunodeficiency
9.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
9.3.2.4. Guillain-Barre Syndrome
9.3.2.5. Myasthenia Gravis
9.3.2.6. Multifocal Motor Neuropathy (MMN)
9.3.2.7. Kawasaki Disease
9.3.2.8. Hypogammaglobulinemia
9.3.2.9. Chronic Lymphocytic Leukemia
9.3.2.10. Others
9.4. Market Analysis, by End-user
9.4.1. Market Value Share Analysis, by End-user
9.4.2. Market Size (US$ Mn) Forecast, by End-user
9.4.2.1. Hospitals
9.4.2.2. Clinics
9.4.2.3. Home Care
9.5. Market Analysis, by Country
9.5.1. Market Value Share Analysis, by Country
9.5.2. Market Size (US$ Mn) Forecast, by Country, 2017–2031
9.5.2.1. U.S.
9.5.2.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Indication
9.6.2. By End-user
9.6.3. By Country
9.7. U.S. Intravenous Immunoglobulin (IVIG) Market Analysis
9.7.1. Market Size (US$ Mn) Forecast, by Indication
9.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9.7.1.2. Primary Humoral Immunodeficiency
9.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
9.7.1.4. Guillain-Barre Syndrome
9.7.1.5. Myasthenia Gravis
9.7.1.6. Multifocal Motor Neuropathy (MMN)
9.7.1.7. Kawasaki Disease
9.7.1.8. Hypogammaglobulinemia
9.7.1.9. Chronic Lymphocytic Leukemia
9.7.1.10. Others
9.7.2. Market Size (US$ Mn) Forecast, by End-user
9.7.2.1. Hospitals
9.7.2.2. Clinics
9.7.2.3. Home Care Settings
9.8. Canada Intravenous Immunoglobulin (IVIG) Market Analysis
9.8.1. Market Size (US$ Mn) Forecast, by Indication
9.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
9.8.1.2. Primary Humoral Immunodeficiency
9.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
9.8.1.4. Guillain-Barre Syndrome
9.8.1.5. Myasthenia Gravis
9.8.1.6. Multifocal Motor Neuropathy (MMN)
9.8.1.7. Kawasaki Disease
9.8.1.8. Hypogammaglobulinemia
9.8.1.9. Chronic Lymphocytic Leukemia
9.8.1.10. Others
9.8.2. Market Size (US$ Mn) Forecast, by End-user
9.8.2.1. Hospitals
9.8.2.2. Clinics
9.8.2.3. Home Care Settings
10. Europe Intravenous Immunoglobulin (IVIG) Market Analysis
10.1. Key Findings
10.2. Market Overview
10.3. Market Analysis, by Indication
10.3.1. Market Value Share Analysis, by Indication
10.3.2. Market Size (US$ Mn) Forecast, by Indication
10.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.3.2.2. Primary Humoral Immunodeficiency
10.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.3.2.4. Guillain-Barre Syndrome
10.3.2.5. Myasthenia Gravis
10.3.2.6. Multifocal Motor Neuropathy (MMN)
10.3.2.7. Kawasaki Disease
10.3.2.8. Hypogammaglobulinemia
10.3.2.9. Chronic Lymphocytic Leukemia
10.3.2.10. Others
10.4. Market Analysis, by End-user
10.4.1. Market Value Share Analysis, by End-user
10.4.2. Market Size (US$ Mn) Forecast, by End-user
10.4.2.1. Hospitals
10.4.2.2. Clinics
10.4.2.3. Home Care
10.5. Market Analysis, by Country/Sub-region
10.5.1. Market Value Share Analysis, by Country/Sub-region
10.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
10.5.2.1. U.K.
10.5.2.2. Germany
10.5.2.3. France
10.5.2.4. Spain
10.5.2.5. Italy
10.5.2.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Indication
10.6.2. By End-user
10.6.3. By Country/Sub-region
10.7. U.K. Intravenous Immunoglobulin (IVIG) Market Analysis
10.7.1. Market Size (US$ Mn) Forecast, by Indication
10.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.7.1.2. Primary Humoral Immunodeficiency
10.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.7.1.4. Guillain-Barre Syndrome
10.7.1.5. Myasthenia Gravis
10.7.1.6. Multifocal Motor Neuropathy (MMN)
10.7.1.7. Kawasaki Disease
10.7.1.8. Hypogammaglobulinemia
10.7.1.9. Chronic Lymphocytic Leukemia
10.7.1.10. Others
10.7.2. Market Size (US$ Mn) Forecast, by End-user
10.7.2.1. Hospitals
10.7.2.2. Clinics
10.7.2.3. Home Care Settings
10.8. Germany Intravenous Immunoglobulin (IVIG) Market Analysis
10.8.1. Market Size (US$ Mn) Forecast, by Indication
10.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.8.1.2. Primary Humoral Immunodeficiency
10.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.8.1.4. Guillain-Barre Syndrome
10.8.1.5. Myasthenia Gravis
10.8.1.6. Multifocal Motor Neuropathy (MMN)
10.8.1.7. Kawasaki Disease
10.8.1.8. Hypogammaglobulinemia
10.8.1.9. Chronic Lymphocytic Leukemia
10.8.1.10. Others
10.8.2. Market Size (US$ Mn) Forecast, by End-user
10.8.2.1. Hospitals
10.8.2.2. Clinics
10.8.2.3. Home Care Settings
10.9. France Intravenous Immunoglobulin (IVIG) Market Analysis
10.9.1. Market Size (US$ Mn) Forecast, by Indication
10.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.9.1.2. Primary Humoral Immunodeficiency
10.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.9.1.4. Guillain-Barre Syndrome
10.9.1.5. Myasthenia Gravis
10.9.1.6. Multifocal Motor Neuropathy (MMN)
10.9.1.7. Kawasaki Disease
10.9.1.8. Hypogammaglobulinemia
10.9.1.9. Chronic Lymphocytic Leukemia
10.9.1.10. Others
10.9.2. Market Size (US$ Mn) Forecast, by End-user
10.9.2.1. Hospitals
10.9.2.2. Clinics
10.9.2.3. Home Care Settings
10.10. Spain Intravenous Immunoglobulin (IVIG) Market Analysis
10.10.1. Market Size (US$ Mn) Forecast, by Indication
10.10.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.10.1.2. Primary Humoral Immunodeficiency
10.10.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.10.1.4. Guillain-Barre Syndrome
10.10.1.5. Myasthenia Gravis
10.10.1.6. Multifocal Motor Neuropathy (MMN)
10.10.1.7. Kawasaki Disease
10.10.1.8. Hypogammaglobulinemia
10.10.1.9. Chronic Lymphocytic Leukemia
10.10.1.10. Others
10.10.2. Market Size (US$ Mn) Forecast, by End-user
10.10.2.1. Hospitals
10.10.2.2. Clinics
10.10.2.3. Home Care Settings
10.11. Italy Intravenous Immunoglobulin (IVIG) Market Analysis
10.11.1. Market Size (US$ Mn) Forecast, by Indication
10.11.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.11.1.2. Primary Humoral Immunodeficiency
10.11.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.11.1.4. Guillain-Barre Syndrome
10.11.1.5. Myasthenia Gravis
10.11.1.6. Multifocal Motor Neuropathy (MMN)
10.11.1.7. Kawasaki Disease
10.11.1.8. Hypogammaglobulinemia
10.11.1.9. Chronic Lymphocytic Leukemia
10.11.1.10. Others
10.11.2. Market Size (US$ Mn) Forecast, by End-user
10.11.2.1. Hospitals
10.11.2.2. Clinics
10.11.2.3. Home Care Settings
10.12. Rest of Europe Intravenous Immunoglobulin (IVIG) Market Analysis
10.12.1. Market Size (US$ Mn) Forecast, by Indication
10.12.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
10.12.1.2. Primary Humoral Immunodeficiency
10.12.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
10.12.1.4. Guillain-Barre Syndrome
10.12.1.5. Myasthenia Gravis
10.12.1.6. Multifocal Motor Neuropathy (MMN)
10.12.1.7. Kawasaki Disease
10.12.1.8. Hypogammaglobulinemia
10.12.1.9. Chronic Lymphocytic Leukemia
10.12.1.10. Others
10.12.2. Market Size (US$ Mn) Forecast, by End-user
10.12.2.1. Hospitals
10.12.2.2. Clinics
10.12.2.3. Home Care Settings
11. Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis
11.1. Key Findings
11.2. Market Overview
11.3. Market Analysis, by Indication
11.3.1. Market Value Share Analysis, by Indication
11.3.2. Market Size (US$ Mn) Forecast, by Indication
11.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.3.2.2. Primary Humoral Immunodeficiency
11.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.3.2.4. Guillain-Barre Syndrome
11.3.2.5. Myasthenia Gravis
11.3.2.6. Multifocal Motor Neuropathy (MMN)
11.3.2.7. Kawasaki Disease
11.3.2.8. Hypogammaglobulinemia
11.3.2.9. Chronic Lymphocytic Leukemia
11.3.2.10. Others
11.4. Market Analysis, by End-user
11.4.1. Market Value Share Analysis, by End-user
11.4.2. Market Size (US$ Mn) Forecast, by End-user
11.4.2.1. Hospitals
11.4.2.2. Clinics
11.4.2.3. Home Care
11.5. Market Analysis, by Country/Sub-region
11.5.1. Market Value Share Analysis, by Country/Sub-region
11.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
11.5.2.1. China
11.5.2.2. Japan
11.5.2.3. Australia
11.5.2.4. India
11.5.2.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Indication
11.6.2. By End-user
11.6.3. By Country/Sub-region
11.7. China Intravenous Immunoglobulin (IVIG) Market Analysis
11.7.1. Market Size (US$ Mn) Forecast, by Indication
11.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.7.1.2. Primary Humoral Immunodeficiency
11.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.7.1.4. Guillain-Barre Syndrome
11.7.1.5. Myasthenia Gravis
11.7.1.6. Multifocal Motor Neuropathy (MMN)
11.7.1.7. Kawasaki Disease
11.7.1.8. Hypogammaglobulinemia
11.7.1.9. Chronic Lymphocytic Leukemia
11.7.1.10. Others
11.7.2. Market Size (US$ Mn) Forecast, by End-user
11.7.2.1. Hospitals
11.7.2.2. Clinics
11.7.2.3. Home Care Settings
11.8. Japan Intravenous Immunoglobulin (IVIG) Market Analysis
11.8.1. Market Size (US$ Mn) Forecast, by Indication
11.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.8.1.2. Primary Humoral Immunodeficiency
11.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.8.1.4. Guillain-Barre Syndrome
11.8.1.5. Myasthenia Gravis
11.8.1.6. Multifocal Motor Neuropathy (MMN)
11.8.1.7. Kawasaki Disease
11.8.1.8. Hypogammaglobulinemia
11.8.1.9. Chronic Lymphocytic Leukemia
11.8.1.10. Others
11.8.2. Market Size (US$ Mn) Forecast, by End-user
11.8.2.1. Hospitals
11.8.2.2. Clinics
11.8.2.3. Home Care Settings
11.9. Australia Intravenous Immunoglobulin (IVIG) Market Analysis
11.9.1. Market Size (US$ Mn) Forecast, by Indication
11.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.9.1.2. Primary Humoral Immunodeficiency
11.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.9.1.4. Guillain-Barre Syndrome
11.9.1.5. Myasthenia Gravis
11.9.1.6. Multifocal Motor Neuropathy (MMN)
11.9.1.7. Kawasaki Disease
11.9.1.8. Hypogammaglobulinemia
11.9.1.9. Chronic Lymphocytic Leukemia
11.9.1.10. Others
11.9.2. Market Size (US$ Mn) Forecast, by End-user
11.9.2.1. Hospitals
11.9.2.2. Clinics
11.9.2.3. Home Care Settings
11.10. India Intravenous Immunoglobulin (IVIG) Market Analysis
11.10.1. Market Size (US$ Mn) Forecast, by Indication
11.10.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.10.1.2. Primary Humoral Immunodeficiency
11.10.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.10.1.4. Guillain-Barre Syndrome
11.10.1.5. Myasthenia Gravis
11.10.1.6. Multifocal Motor Neuropathy (MMN)
11.10.1.7. Kawasaki Disease
11.10.1.8. Hypogammaglobulinemia
11.10.1.9. Chronic Lymphocytic Leukemia
11.10.1.10. Others
11.10.2. Market Size (US$ Mn) Forecast, by End-user
11.10.2.1. Hospitals
11.10.2.2. Clinics
11.10.2.3. Home Care Settings
11.11. Rest of Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis
11.11.1. Market Size (US$ Mn) Forecast, by Indication
11.11.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
11.11.1.2. Primary Humoral Immunodeficiency
11.11.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
11.11.1.4. Guillain-Barre Syndrome
11.11.1.5. Myasthenia Gravis
11.11.1.6. Multifocal Motor Neuropathy (MMN)
11.11.1.7. Kawasaki Disease
11.11.1.8. Hypogammaglobulinemia
11.11.1.9. Chronic Lymphocytic Leukemia
11.11.1.10. Others
11.11.2. Market Size (US$ Mn) Forecast, by End-user
11.11.2.1. Hospitals
11.11.2.2. Clinics
11.11.2.3. Home Care Settings
12. Latin America Intravenous Immunoglobulin (IVIG) Market Analysis
12.1. Key Findings
12.2. Market Overview
12.3. Market Analysis, by Indication
12.3.1. Market Value Share Analysis, by Indication
12.3.2. Market Size (US$ Mn) Forecast, by Indication
12.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.3.2.2. Primary Humoral Immunodeficiency
12.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
12.3.2.4. Guillain-Barre Syndrome
12.3.2.5. Myasthenia Gravis
12.3.2.6. Multifocal Motor Neuropathy (MMN)
12.3.2.7. Kawasaki Disease
12.3.2.8. Hypogammaglobulinemia
12.3.2.9. Chronic Lymphocytic Leukemia
12.3.2.10. Others
12.4. Market Analysis, by End-user
12.4.1. Market Value Share Analysis, by End-user
12.4.2. Market Size (US$ Mn) Forecast, by End-user
12.4.2.1. Hospitals
12.4.2.2. Clinics
12.4.2.3. Home Care
12.5. Market Analysis, by Country/Sub-region
12.5.1. Market Value Share Analysis, by Country/Sub-region
12.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
12.5.2.1. Brazil
12.5.2.2. Mexico
12.5.2.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Indication
12.6.2. By End-user
12.6.3. By Country/Sub-region
12.7. Brazil Intravenous Immunoglobulin (IVIG) Market Analysis
12.7.1. Market Size (US$ Mn) Forecast, by Indication
12.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.7.1.2. Primary Humoral Immunodeficiency
12.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
12.7.1.4. Guillain-Barre Syndrome
12.7.1.5. Myasthenia Gravis
12.7.1.6. Multifocal Motor Neuropathy (MMN)
12.7.1.7. Kawasaki Disease
12.7.1.8. Hypogammaglobulinemia
12.7.1.9. Chronic Lymphocytic Leukemia
12.7.1.10. Others
12.7.2. Market Size (US$ Mn) Forecast, by End-user
12.7.2.1. Hospitals
12.7.2.2. Clinics
12.7.2.3. Home Care Settings
12.8. Mexico Intravenous Immunoglobulin (IVIG) Market Analysis
12.8.1. Market Size (US$ Mn) Forecast, by Indication
12.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.8.1.2. Primary Humoral Immunodeficiency
12.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
12.8.1.4. Guillain-Barre Syndrome
12.8.1.5. Myasthenia Gravis
12.8.1.6. Multifocal Motor Neuropathy (MMN)
12.8.1.7. Kawasaki Disease
12.8.1.8. Hypogammaglobulinemia
12.8.1.9. Chronic Lymphocytic Leukemia
12.8.1.10. Others
12.8.2. Market Size (US$ Mn) Forecast, by End-user
12.8.2.1. Hospitals
12.8.2.2. Clinics
12.8.2.3. Home Care Settings
12.9. Rest of Latin America Intravenous Immunoglobulin (IVIG) Market Analysis
12.9.1. Market Size (US$ Mn) Forecast, by Indication
12.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12.9.1.2. Primary Humoral Immunodeficiency
12.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
12.9.1.4. Guillain-Barre Syndrome
12.9.1.5. Myasthenia Gravis
12.9.1.6. Multifocal Motor Neuropathy (MMN)
12.9.1.7. Kawasaki Disease
12.9.1.8. Hypogammaglobulinemia
12.9.1.9. Chronic Lymphocytic Leukemia
12.9.1.10. Others
12.9.2. Market Size (US$ Mn) Forecast, by End-user
12.9.2.1. Hospitals
12.9.2.2. Clinics
12.9.2.3. Home Care Settings
13. Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis
13.1. Key Findings
13.2. Market Overview
13.3. Market Analysis, by Indication
13.3.1. Market Value Share Analysis, by Indication
13.3.2. Market Size (US$ Mn) Forecast, by Indication
13.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.3.2.2. Primary Humoral Immunodeficiency
13.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP)
13.3.2.4. Guillain-Barre Syndrome
13.3.2.5. Myasthenia Gravis
13.3.2.6. Multifocal Motor Neuropathy (MMN)
13.3.2.7. Kawasaki Disease
13.3.2.8. Hypogammaglobulinemia
13.3.2.9. Chronic Lymphocytic Leukemia
13.3.2.10. Others
13.4. Market Analysis, by End-user
13.4.1. Market Value Share Analysis, by End-user
13.4.2. Market Size (US$ Mn) Forecast, by End-user
13.4.2.1. Hospitals
13.4.2.2. Clinics
13.4.2.3. Home Care
13.5. Market Analysis, by Country/Sub-region
13.5.1. Market Value Share Analysis, by Country/Sub-region
13.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
13.5.2.1. GCC Countries
13.5.2.2. South Africa
13.5.2.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Indication
13.6.2. By End-user
13.6.3. By Country/Sub-region
13.7. GCC Countries Intravenous Immunoglobulin (IVIG) Market Analysis
13.7.1. Market Size (US$ Mn) Forecast, by Indication
13.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.7.1.2. Primary Humoral Immunodeficiency
13.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
13.7.1.4. Guillain-Barre Syndrome
13.7.1.5. Myasthenia Gravis
13.7.1.6. Multifocal Motor Neuropathy (MMN)
13.7.1.7. Kawasaki Disease
13.7.1.8. Hypogammaglobulinemia
13.7.1.9. Chronic Lymphocytic Leukemia
13.7.1.10. Others
13.7.2. Market Size (US$ Mn) Forecast, by End-user
13.7.2.1. Hospitals
13.7.2.2. Clinics
13.7.2.3. Home Care Settings
13.8. South Africa Intravenous Immunoglobulin (IVIG) Market Analysis
13.8.1. Market Size (US$ Mn) Forecast, by Indication
13.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.8.1.2. Primary Humoral Immunodeficiency
13.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
13.8.1.4. Guillain-Barre Syndrome
13.8.1.5. Myasthenia Gravis
13.8.1.6. Multifocal Motor Neuropathy (MMN)
13.8.1.7. Kawasaki Disease
13.8.1.8. Hypogammaglobulinemia
13.8.1.9. Chronic Lymphocytic Leukemia
13.8.1.10. Others
13.8.2. Market Size (US$ Mn) Forecast, by End-user
13.8.2.1. Hospitals
13.8.2.2. Clinics
13.8.2.3. Home Care Settings
13.9. Rest of Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis
13.9.1. Market Size (US$ Mn) Forecast, by Indication
13.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
13.9.1.2. Primary Humoral Immunodeficiency
13.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP)
13.9.1.4. Guillain-Barre Syndrome
13.9.1.5. Myasthenia Gravis
13.9.1.6. Multifocal Motor Neuropathy (MMN)
13.9.1.7. Kawasaki Disease
13.9.1.8. Hypogammaglobulinemia
13.9.1.9. Chronic Lymphocytic Leukemia
13.9.1.10. Others
13.9.2. Market Size (US$ Mn) Forecast, by End-user
13.9.2.1. Hospitals
13.9.2.2. Clinics
13.9.2.3. Home Care Settings
14. Company Profiles
14.1. Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2021)
14.2. Competition Matrix
14.3. Company Profiles
14.3.1. Baxalta Incorporated
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Biotest AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. China Biologic Products, Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. CSL Behring LLC
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Grifols S.A.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Kedrion S.p.A.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. LFB Biomedicaments S.A.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Octapharma AG
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. Sanquin Plasma Products B.V.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview

List of Tables
Table 01: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 02: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 03: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 05: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 06: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 07: U.S. Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 08: U.S. Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Canada Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 10: Canada Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 11: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 12: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: U.K. Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 15: U.K. Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 16: Germany Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 17: Germany Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 18: France Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 19: France Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 20: Spain Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 21: Spain Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 22: Italy Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 23: Italy Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 24: Rest of Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 25: Rest of Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 26: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 27: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 28: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 29: China Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 30: China Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 31: Japan Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 32: Japan Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 33: India Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 34: India Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 35: Australia & New Zealand Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 36: Australia & New Zealand Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 37: Rest of Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 38: Rest of Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 39: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 40: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 41: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 42: Brazil Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 43: Brazil Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 44: Mexico Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 45: Mexico Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 46: Rest of Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 47: Rest of Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 48: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication Type, 2017–2031
Table 49: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 50: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 51: GCC Countries Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 52: GCC Countries Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 53: South Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 54: South Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 55: Rest of Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 56: Rest of Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2017–2031